Contact
  • This website is for a UK audience
  • An LFB Group company
LFB
  • About
    • About LFB BIOPHARMACEUTICALS
    • About LFB Group
      • Therapeutic areas
      • Expert in biopharmaceuticals
      • International development
      • Responsibility to patients & healthcare professionals
  • What we do
    • LFB’s plasma-derived biopharmaceuticals
    • Our products
      • IQYMUNE®▼ (Human normal immunoglobulin)
      • FIBCLOT®▼ (Human fibrinogen)
      • WILLFACT® (Human von Willebrand factor)
      • Adverse event reporting
  • Contact us
    • Adverse event reporting
  • About LFB BIOPHARMACEUTICALS

    LFB BIOPHARMACEUTICALS, takes over the promotion of LFB’s biopharmaceutical products for serious and rare diseases to healthcare professionals, in the United Kingdom.

  • About LFB Group

    LFB is a pharmaceutical group specialising in plasma derived or recombinant therapeutic proteins for the treatment of serious and often rare diseases

  • LFB’s plasma-derived biopharmaceuticals

    LFB’s 15 biopharmaceuticals are used for treating disorders that are always serious and often rare

  • Our products

  • Adverse event reporting

burger
  1. Home
  2. Information notices

Information notices

Privacy Policy

Read more

Modern Slavery Statement

Read more

Cookie Policy

Read more

Terms of Use

Terms of Use

Read more

Carbon Reduction Plan

Read more

  • About
    • About LFB BIOPHARMACEUTICALS
    • About LFB Group
  • What we do
    • LFB’s plasma-derived biopharmaceuticals
    • Our products
      • CEVENFACTA®▼ (Eptacog beta)
      • IQYMUNE®▼ (Human normal immunoglobulin)
      • FIBCLOT®▼ (Human fibrinogen)
      • WILLFACT® (Human von Willebrand factor)
  • Contact us
    • Adverse event reporting
  • LFB Biopharmaceuticals Limited,
    • Suite 106,
      Spirella Building Bridge Road Letchworth Garden City,
      Hertfordshire UK SG6 4ET.
      Registered office: Acre House, 11/15 William Road, London NW1 3ER.
      Registered in England & Wales, no. 6058711
  • Adverse event reporting
  • Information notices
  • Site map
  • Management of personal data
 

 

×